文献速递类风湿关节炎

类风湿关节炎生物制剂减停策略:减量优于停药, flare风险可控且可逆

Risk of disease flare and clinical reversibility following discontinuation versus dose reduction of biological DMARDs in Rheumatoid arthritis: A systematic review and meta-analysis.
PubMed 文献 · Semin Arthritis Rheum · 2026-06-03

完全停药显著增加flare风险(RR 2.13,95%CI 1.74-2.61),但再治疗捕获率达87.5%,影像学进展轻微。建议优先采用逐步减量策略。

要点

  • 完全停用bDMARDs较减量/维持使flare风险增加超过一倍(RR 2.13)。
  • 再治疗捕获率87.5%,中位12.4周临床恢复,提示flare后果可逆。
  • 影像学进展轻微,主要由flare期间累积疾病活动驱动,而非减停策略本身。

核心结论

  • 对于维持缓解的RA患者,逐步减量是比完全停用更安全的初始降阶梯策略。
  • 停用bDMARDs虽使flare风险翻倍以上,但临床后果大部分可逆。

研究设计与样本

  • 系统评价与荟萃分析,检索PubMed、Embase和Cochrane Library截至2026年2月1日的随机对照试验。

主要发现

  • 完全停用bDMARDs较减量或维持策略显著增加flare风险(Pooled RR 2.13;95% CI 1.74-2.61;P < 0.00001)。
  • 病程亚组分析显示显著交互作用(P = 0.007):早期RA(<2年)flare风险RR 1.62(95% CI 1.25-2.10), established RA风险RR 2.31(95% CI 1.89-2.82)。
  • 再治疗捕获率为87.5%(95% CI 82.4-91.6),中位12.4周达到临床恢复。
  • 影像学进展轻微,主要由flare期间累积疾病活动驱动而非减停策略本身;Egger检验P = 0.456未检测到显著发表偏倚。

临床怎么用

  • 对达到稳定缓解的RA患者,优先选择逐步减量而非完全停用bDMARDs。
  • 减量过程中应配合严格监测和即时再治疗预案,以平衡无治疗缓解与结构安全。

局限性

  • 纳入研究包含一项10年扩展研究,非全部为RCT。
  • 原文未报告各研究间异质性定量指标(如I²)及具体减量方案差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: For patients with rheumatoid arthritis (RA) who achieve stable remission, a key clinical goal is the de-escalation of biological disease-modifying antirheumatic drugs (bDMARDs). However, the best approach-whether to completely discontinue treatment or to gradually reduce the dose-remains a topic of debate. This systematic review and meta-analysis aimed to compare the risks of flare, clinical reversibility, and radiographic safety associated with these two strategies. METHODS: We conducted a search of PubMed, Embase, and the Cochrane Library for randomized controlled trials (RCTs) published from inception until February 1, 2026. Eleven studies (including 10 RCTs and one 10-year extension study) involving 2861 patients were included. The primary outcome was the risk ratio (RR) of disease flare. Secondary outcomes included the re-treatment success rate (capture rate) and radiographic progression (vSHS). All analyses employed a random-effects model. The study protocol was registered in the PROSPERO database (Registration No CRD420261331554) RESULTS: The pooled meta-analysis revealed that complete discontinuation of bDMARDs significantly increases the risk of flare compared to dose reduction or maintenance strategies (Pooled RR: 2.13; 95% CI: 1.74-2.61; P < 0.00001). Subgroup analysis based on disease duration indicated a significant interaction (P = 0.007); the risk of flare was lower in patients with early RA (<2 years; RR 1.62; 95% CI: 1.25-2.10) compared to those with established RA (RR 2.31; 95% CI: 1.89-2.82). Despite the increased flare risk, the pooled capture rate upon re-initiating therapy was 87.5% (95% CI: 82.4-91.6), with clinical recovery achieved within a median of 12.4 weeks. Radiographic progression was minimal and primarily driven by cumulative disease activity during flares rather than the tapering strategy itself. No significant publication bias was detected (Egger's test, P = 0.456). CONCLUSION: Gradual dose reduction is a safer initial de-escalation strategy than complete discontinuation for maintaining remission in RA. Although stopping bDMARDs more than doubles the risk of flare, the clinical consequences are largely reversible. A stepwise tapering approach, supported by strict monitoring and immediate re-treatment protocols, should be prioritized to balance treatment-free remission with structural safety.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Lee YH, Song GG. Risk of disease flare and clinical reversibility following discontinuation versus dose reduction of biological DMARDs in Rheumatoid arthritis: A systematic review and meta-analysis. Semin Arthritis Rheum. 2026. PMID: 42269230. doi:10.1016/j.semarthrit.2026.153011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。